MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH Patent applications |
Patent application number | Title | Published |
20160109432 | METHODS AND MATERIALS FOR ASSESSING PLURIPOTENCY OF STEM CELL POPULATIONS - This document provides methods and materials for assessing the pluripotency of stem cell populations. For example, methods and materials for using a DNA damaging agent (e.g., etoposide) to assess the pluripotency of a population of stem cells (e.g., a population of human induced pluripotent stem cells) are provided. | 04-21-2016 |
20160096890 | B7-H1, A NOVEL IMMUNOREGULATORY MOLECULE - The invention provides novel polypeptides useful for co-stimulating T cells, isolated nucleic acid molecules encoding them, vectors containing the nucleic acid molecules, and cells containing the vectors. Also included are methods of making and using these co-stimulatory polypeptides. | 04-07-2016 |
20160096889 | B7-H1, A NOVEL IMMUNOREGULATORY MOLECULE - The invention provides novel polypeptides useful for co-stimulating T cells, isolated nucleic acid molecules encoding them, vectors containing the nucleic acid molecules, and cells containing the vectors. Also included are methods of making and using these co-stimulatory polypeptides. | 04-07-2016 |
20160095942 | CARRIER-ANTIBODY COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME - Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. | 04-07-2016 |
20160082025 | USING DNA METHYLTRANSFERASE INHIBITORS TO TREAT CALCIFIC AORTA VALVE DISEASE - Materials and methods for using DNA methyltransferase inhibitors to slow progression of aortic valve calcification and stenosis are provided. | 03-24-2016 |
20160051675 | B7-H4 EXPRESSION ON TUMOR VASCULATURE - Methods of evaluating patients by assessing expression of B7-H4 in the vasculature are described. | 02-25-2016 |
20160038492 | Targeted Therapies for Cancer - Methods of selecting a chemotherapy regimen for treatment of cancer in a patient are disclosed. A patient genetic sample from a bilary cancer such as cholangiocarcinoma is analyzed for a mutation in ERRFI1 and a chemotherapeutic agent is selected as a result of the analysis. If a mutation in ERRFI1 is present, treatment with an inhibitor of Epidermal Growth Factor Receptor (EGFR) is shown to have inhibitory effects on tumor growth. In this manner, the chemotherapy regimen is targeted to a given mutation in a patient's cancer. | 02-11-2016 |
20160022722 | METHODS AND MATERIALS FOR REDUCING THE RISK OF INFECTIONS - This document relates to methods and materials for reducing the risk of infection after a shoulder surgery or medical procedure. For example, this document relates to methods and materials for using a topical composition containing clindamycin or erythromycin to reduce the risk of or to prevent infection associated with shoulder surgeries or medical procedures. | 01-28-2016 |
20160017333 | DNA APTAMERS FOR PROMOTING REMYELINATION - Materials and methods related to using multimeric DNA aptamers to treat demyelinating diseases are provided herein. | 01-21-2016 |
20150374793 | DIURETIC AND NATRIURETIC POLYPEPTIDES - This document provides diuretic and natriuretic polypeptides. For example, this document provides polypeptides having diuretic and/or natriuretic activities. In some cases, a polypeptide provided herein can have diuretic and natriuretic activities, while lacking the ability to lower blood pressure. This document also provides methods and materials for inducing diuretic and/or natriuretic activities within a mammal. | 12-31-2015 |
20150374691 | METHODS AND MATERIALS FOR TREATING ORTHOSTATIC HYPOTENSION OR POSTURAL TACHYCARDIA SYNDROME - This document provides methods and materials related to treating orthostatic hypotension and/or postural tachycardia syndrome. For example, methods and materials for using a composition containing 3,4-diaminopyridine, 4-aminopyridine, or both to treat patients with orthostatic hypotension, postural tachycardia syndrome, or both orthostatic hypotension and postural tachycardia syndrome are provided. | 12-31-2015 |
20150368312 | INSULIN SECRETING POLYPEPTIDES - This document provides methods and materials related to insulin secreting polypeptides. For example, polypeptides having the ability to induce insulin secretion and methods and materials for using use such polypeptides to induce insulin secretion and to treat diabetes are provided. | 12-24-2015 |
20150359803 | METHODS AND MATERIALS FOR REDUCING SUPRESSION OF IMMUNE FUNCTION - This document provides methods and materials involved in reducing suppression of immune function in mammals. For example, methods and materials for (a) identifying a mammal as having an elevated level of CD14 | 12-17-2015 |
20150293119 | ASSESSING RENAL STRUCTURAL ALTERATIONS AND OUTCOMES - This document provides methods and materials involved in assessing renal structural alterations (e.g., renal fibrosis, glomerular basement thickening, mesangial matrix expansion, swollen podocytes, and foot processes effacement) as well as methods and materials involved in assessing outcomes. For example, methods and materials for using the level of urinary CNP (e.g., a urinary to plasma CNP ratio) to determine whether or not a mammal is developing renal structural alterations (e.g., renal fibrosis, glomerular basement thickening, mesangial matrix expansion, swollen podocytes, and foot processes effacement) as well as methods and materials for using the level of urinary CNP levels to identify patients having an increased likelihood of experiencing a poor outcome are provided. | 10-15-2015 |
20150273011 | TOPICAL CORNEAL ANALGESIA USING NEUROTENSIN RECEPTOR AGONISTS AND SYNERGISTIC NEUROTENSIN COMBINATIONS WITHOUT DELAYING WOUND HEALING - A method for administering an ocular analgesic is described. The method includes the steps of providing a topical analgesic that includes a neo-tryptophan-containing neurotensin analog and applying the topical analgesic to the ocular tissue in a dose of about 0.0001 to about 5 mg, alternatively about 0.0001 to about 3 mg, alternatively about 0.0005 to about 1.2 mg, alternatively about 0.0005 to about 1.0 mg, alternatively about 0.00075 to about 1.0 mg, alternatively about 0.001 mg to about 1.0 mg, alternatively about 0.001 mg to about 0.8 mg, alternatively about 0.001 mg to about 0.7 mg, alternatively about 0.001 mg to about 0.6 mg. Methods of administering a topical analgesic containing a neo-tryptophan-containing neurotensin analog are also described. The topical analgesic can be administered in a patch, gel, lotion, spray, or mist. | 10-01-2015 |
20150232533 | B7-H1, A NOVEL IMMUNOREGULATORY MOLECULE - The invention provides novel polypeptides useful for co-stimulating T cells, isolated nucleic acid molecules encoding them, vectors containing the nucleic acid molecules, and cells containing the vectors. Also included are methods of making and using these co-stimulatory polypeptides. | 08-20-2015 |
20150231218 | METHODS AND MATERIALS FOR GENERATING CD8+ T CELLS HAVING THE ABILITY TO RECOGNIZE CANCER CELLS EXPRESSING A HER2/NEU POLYPEPTIDE - This document provides methods and materials for generating CD8 | 08-20-2015 |
20150223795 | LAPAROSCOPIC RETRACTOR DEVICES - Devices for performing medical procedures such as laparoscopic surgery are provided herein. For example, this document provides laparoscopic retractor devices. In some embodiments, the laparoscopic retractor devices provided herein include two retractor blades that can be expanded or contracted. Further, in some embodiments an elastic covering is included, and the retractor blades are disposed within the elastic covering. | 08-13-2015 |
20150203564 | B7-H5, A Costimulatory Polypeptide - B7-H5 costimulatory polypeptides, nucleic acids encoding such polypeptides, and methods for using the polypeptides and nucleic acids to enhance a T cell response are provided herein. | 07-23-2015 |
20150191789 | METHODS AND MATERIALS FOR IDENTIFYING MAMMALS HAVING PROSTATE CANCER - This document provides methods and materials related to identifying prostate cancer in male mammals. For example, methods and materials for assessing a benign prostate sample (e.g., benign prostate tissue or cells) to determine whether or not a mammal has prostate cancer are provided. | 07-09-2015 |
20150181844 | FUMARYLACETOACETATE HYDROLASE (FAH)-DEFICIENT PIGS AND USES THEREOF - Described herein is the generation of Fah | 07-02-2015 |
20150174242 | MONOVALENT ANTI-CD3 ADJUVANTS - This document provides methods and materials related to using monovalent anti-CD3 antibodies (e.g., monovalent anti-CD3 Fab fragments) as adjuvants to increase the immune response produced against an antigen (e.g., a tumor associated antigen). For example, vaccine compositions containing monovalent anti-CD3γε Fab fragments in combination with tumor associated antigens (e.g., tumor associated antigens having little or no immunogenicity in the absence of monovalent anti-CD3γε Fab fragments) alone or in combination with adjuvants for signals two and/or three required for full activation of T cell immune function, as well as methods and materials for using monovalent anti-CD3γε Fab fragments to increase the immune response produced against an antigen (e.g., a tumor associated antigen) within a mammal (e.g., a human) are provided. | 06-25-2015 |
20150153322 | VITAMIN D DEFICIENCIES - Methods for determining the amount of vitamin D compounds in a sample are provided. The methods can employ LC-MS/MS techniques and optionally the use of deuterated internal standards. Methods for diagnosing vitamin D deficiencies are also provided. | 06-04-2015 |
20150148821 | THORASCOPIC HEART VALVE REPAIR METHOD AND APPARATUS - An instrument for performing thorascopic repair of heart valves includes a shaft for extending through the chest cavity and into a heart chamber providing access to a valve needing repair. A movable tip on the shaft is operable to capture a valve leaflet and a needle is operable to penetrate a capture valve leaflet and draw the suture therethrough. The suture is thus fastened to the valve leaflet and the instrument is withdrawn from the heart chamber transporting the suture outside the heart chamber. The suture is anchored to the heart wall with proper tension as determined by observing valve operation with an ultrasonic imaging system. | 05-28-2015 |
20150119661 | METHOD AND APPARATUS FOR SELECTING WAVELENGTHS FOR OPTICAL MEASUREMENTS OF A PROPERTY OF A MOLECULAR ANALYTE - A system and optimization algorithm for determining the preferred operational wavelengths of a device configured for measurement of molecular analytes in a sample. Operational wavelengths are determined by solving a system of equations linking empirically defined functions representative of these analytes, spectrally dependent coefficients corresponding to these analytes, path lengths traversed by waves probing the analytes at wavelengths corresponding to the absorption level described by the functions representative of these analytes, and, optionally, a cost-function taking into account at least one of spectral separation between the operational wavelengths, manufacturability of wave source(s) producing wave(s) at operational wavelength(s), and the noise factor associated with the operation of such wave source(s). | 04-30-2015 |
20150119413 | TREATMENT OF POLYCYSTIC DISEASES WITH AN HDAC6 INHIBITOR - An HDAC6-specific inhibitor (i.e., a compound of Formula I or II) is shown to reduce the pathogenesis associated with polycystic disease. Administration of an HDAC6-specific inhibitor attenuated many of the symptoms characteristic of polycystic liver disease including cyst formation, cyst growth and cholangiocyte proliferation. Treatment with a HDAC6-specific inhibitor also increased the amount of bile duct acetylated tubulin and β-catenin phosphorylation and/or acetylation while reducing bile duct β-catenin synthesis. These results demonstrate that HDAC6 is overexpressed in cystic cholangiocytes and that its pharmacological inhibition reduces cholangiocyte proliferation and cyst growth. | 04-30-2015 |
20150111232 | Soluble B7-H1 - This document features methods of evaluating mammals by assessing expression of B7-H1 in a body fluid. | 04-23-2015 |
20150105640 | NON-INVASIVE MONITORING OF PHYSIOLOGICAL CONDITIONS - This document provides methods and materials related to the non-invasive measurement of analytes in blood. | 04-16-2015 |
20150104331 | CANNULA APPARATUS AND VENTRICULAR ASSIST SYSTEMS USING THE CANNULA APPARATUS - Cannula apparatus, ventricular assist systems including the cannula apparatus, and methods of priming and placing the cannula apparatus and ventricular assist systems are described herein. | 04-16-2015 |
20150094787 | METHODS AND MATERIALS FOR TREATING SYNCOPE - This document provides methods and materials for treating syncope (e.g., neurocardiogenic syncope). For example, methods and materials involved in using electrical techniques to stimulate nerves (e.g., renal efferent and/or afferent nerves) in a manner that results in systemic blood vessel constriction and/or increased blood pressure are provided. | 04-02-2015 |
20150080314 | TOPICAL CORNEAL ANALGESIA USING NEUROTENSIN RECEPTOR AGONISTS AND SYNERGISTIC NEUROTENSIN COMBINATIONS WITHOUT DELAYING WOUND HEALING - Ocular analgesics for topical administration are described. The topical ocular analgesic includes a neo-tryptophan-containing neurotensin analog. The topical ocular analgesic may alternatively include a buffered salt solution, a local anesthetic solution, a tissue penetrating agent, and/or an opiate. The neo-tryptophan-containing neurotensin analog may be present in a dose of about 0.0005 to about 1.2 mg. | 03-19-2015 |
20150079595 | METHODS AND MATERIALS FOR DETECTING GENE AMPLIFICATION - This document relates to methods and materials involved in detecting gene amplification in a mammal. For example, methods and materials for detecting amplification at CPM and MDM2 loci to determine the presence or absence of a malignant lipomatous neoplasm in a mammal are provided. | 03-19-2015 |
20150037796 | TBL1XR1 AND TP63 TRANSLOCATIONS - This document provides methods and materials involved in detecting translocations of TBL1XR1 and TP63 nucleic acid. For example, methods and materials for detecting TBL1XR1 and TP63 gene rearrangements (e.g., translocations) associated with cancer (e.g., T-cell lymphomas) as well as methods and materials for detecting cancers (e.g., T-cell lymphomas) with a dominant negative TP63 phenotype are provided. | 02-05-2015 |
20150031757 | TREATING GLAUCOMA, CARDIOVASCULAR DISEASES, AND RENAL DISEASES - This document provides methods and materials related to treating glaucoma, ocular hypertension, cardiovascular diseases, and renal diseases. For example, this document provides isolated nucleic acid molecules and viral vectors (e.g., lentiviral vectors) containing isolated nucleic acid molecules. Methods for reducing intraocular pressure as well as symptoms and progression of cardiovascular and renal diseases also are provided. | 01-29-2015 |
20150024420 | EXTRACELLULAR AND MEMBRANE-ASSOCIATED PROSTATE CANCER MARKERS - This document relates to methods and materials involved in identifying, assessing, and monitoring prostate cancer in male mammals. For example, this document provides arrays for detecting polypeptides or nucleic acids that can be used to identify prostate cancer in male mammals. In addition, methods and materials for assessing and monitoring prostate cancer in mammals are provided herein. | 01-22-2015 |
20150010927 | DETECTING LATENT TUBERCULOSIS INFECTIONS - This document provides methods and materials related to identifying mammals having a LTBI. For example, methods and materials for using ELISpot assays to identify mammals (e.g., humans) having a LTBI are provided. | 01-08-2015 |
20140369955 | METHODS FOR AUTOLOGOUS STEM CELL TRANSPLANTATION - Materials and methods for obtaining populations of lymphocytes and administering the population of lymphocytes to a subject are disclosed herein. In particular, disclosed herein are materials and methods for obtaining lymphocyte populations that contain at least about 0.5×10 | 12-18-2014 |
20140329760 | PEPTIDES AND NANOPARTICLES FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS - Provided herein are peptides and nanoparticles conjugates thereof useful for the treatment of diseases and disorders mediated by GIPC/synectin, such as cancer. | 11-06-2014 |
20140328866 | Peptide-Mediated Non-Covalent Delivery of Active Agents Across the Blood-Brain Barrier - The peptides described herein can function as carrier peptides. These peptides can associate with (e.g., non-covalently bind) biologically active molecules or imaging agents to transport the biologically active molecules or imaging across the blood-brain barrier. In some cases, such transport may increase the effectiveness of the biological molecules or imaging agents. | 11-06-2014 |
20140323800 | VESSEL DISSECTION AND HARVESTING APPARATUS, SYSTEMS AND METHODS - Apparatus, systems, and methods for endoscopic dissection of blood vessels and control over cavity pressure within an endoscopic procedure are described herein. Apparatus, systems, and methods for harvesting of blood vessels are also described herein. | 10-30-2014 |
20140323333 | FLOW CYTOMETRY ASSAY METHODS - This document provides methods and materials involved in performing flow cytometry assay methods. For example, flow cytometry assay methods and kits are provided. | 10-30-2014 |
20140316225 | SYSTEM AND METHOD FOR DETECTING VASCULAR CONTAMINATION BY SURGICAL ANESTHETIC USING NON-INVASIVE IR SPECTROPHOTOMETRY - A system and method for detecting vascular contamination by surgical anesthetic using non-invasive IR spectrophotometry. One embodiment is a method for operating an instrument such as an enhanced pulse oximeter to monitor a patient receiving local anesthetic marked with dye that absorbs infrared light. Light is applied to and detected from tissue of the patient. A signal representative of the detected light is processed to derive patient oxygenation information. The detected light is also processed to derive information representative of the presence of the dye-marked anesthetic. The oxygenation information and the information representative of the presence of anesthetic are displayed. The oxygenation monitoring and display and the anesthetic monitoring and display can occur separately or concurrently. Fluorescing dyes and fluorescence detection approaches are used for anesthetic detection in some embodiments. Other embodiments apply a sequence of light pulses and correlate the applied light pulse sequence to the detected signal to identify the presence of the dye-marked anesthetic. | 10-23-2014 |
20140315863 | TREATING BLADDER CANCER PATIENTS AND IDENTIFYING BLADDER CANCER PATIENTS RESPONSIVE TO TREATMENT - This documents provided methods and materials involved in treating bladder cancer. This document also provides methods and materials involved in identifying bladder cancer patients likely or unlikely to respond to treatment (e.g., BCG therapy). | 10-23-2014 |
20140315225 | METHODS AND COMPOSITIONS FOR DETECTING THE PRESENCE OF ONE OR MORE AUTOANTIBODIES - This disclosure describes methods and compositions for immunohistochemically detecting the presence of a SRP autoantibody in a biological sample. | 10-23-2014 |
20140314796 | MARKER FOR NEUROMYELITIS OPTICA - The present invention provides for methods and materials for diagnosing and treating neuromyelitis optica (NMO). | 10-23-2014 |
20140314663 | PEPTIDE-MEDIATED DELIVERY OF ACTIVE AGENTS ACROSS THE BLOOD-BRAIN BARRIER - Provided herein are methods for transporting an active agent (e.g., a therapeutic agent or an imaging agent) across the blood-brain barrier (BBB) in a patient. For example, the methods provided herein can be used to treat a brain disease in a patient, such as brain cancer. In some embodiments, the methods provided herein can be used to image the central nervous system of a patient. | 10-23-2014 |
20140274937 | METHODS OF TREATING HEMATOLOGIC CANCERS - This disclosure relates to the treatment of hematologic cancers, for example, cancers of the blood, by methods that include administration of EGCG and at least one of a purine nucleoside analog and an alkylating agent. In particular, methods of treating chronic lymphocytic leukemia (CLL) and acute lymphocytic leukemia (ALL) are described. | 09-18-2014 |
20140274901 | PROANP COMPOSITIONS AND METHODS FOR TREATING ACUTE HEART FAILURE - Materials and Methods related to using proANP to treat cardiorenal disease, including acute heart failure. | 09-18-2014 |
20140274748 | DETECTING NEOPLASM - Provided herein is technology relating to detecting neoplasia and particularly, but not exclusively, to methods, compositions, and related uses for detecting premalignant and malignant neoplasms such as pancreatic and colorectal cancer. | 09-18-2014 |
20140271674 | METHODS AND MATERIALS FOR TREATING CANCER - This document provides methods and materials involved in treating cancer. For example, methods and materials for identifying a mammal as having an elevated level of PD-1 | 09-18-2014 |
20140271456 | RADIOTRACER IMAGING USING SODIUM IODIDE SYMPORTER POLYPEPTIDES - This document provides methods and materials involved in radiotracer imaging using NIS polypeptides. For example, methods and materials for performing imaging techniques that increase the detection sensitivity and resolution of radiotracers localized by NIS reporter gene expression and/or decrease background signals that can be attributed to endogenously expressed NIS polypeptides are provided. | 09-18-2014 |
20140255936 | DETECTING FRONTOTEMPORAL DEMENTIA AND AMYOTROPHIC LATERAL SCLEROSIS - This document provides methods and materials for detecting a nucleic acid expansion. For example, methods and materials for detecting the presence of an expanded number (e.g., greater than 30, 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, or more copies) of a hexanucleotide repeat (e.g., GGGGCC) in the non-coding region of a C9ORF72 gene are provided. | 09-11-2014 |
20140239045 | SURGICAL STAPLER DELIVERY SYSTEMS AND METHODS OF ASSEMBLING THE STAPLERS - Surgical stapler delivery systems and methods of using the delivery systems to deliver and assemble surgical staplers are described herein. | 08-28-2014 |
20140234943 | Viruses Lacking Epithelial Cell Receptor Entry - The document provides nucleic acids, polypeptides, and viruses containing nucleic acids and/or polypeptides. The document also provides methods for using viruses to treat cancer patients. Specifically, the document provides nucleic acid molecules encoding viral hemagglutinin (H) polypeptides, viral H polypeptides, and viruses containing nucleic acids and/or H polypeptides. Such viruses are useful for vaccinations and for treating cancer patients as the viruses are not shed. | 08-21-2014 |
20140234352 | B7-H3 AND B7-H4, NOVEL IMMUNOREGULATORY MOLECULES - The invention provides novel B7-H3 and B7-H4 polypeptides useful for co-stimulating T cells, isolated nucleic acid molecules encoding them, vectors containing the nucleic acid molecules, and cells containing the vectors. Also included are methods of making and using these co-stimulatory polypeptides. | 08-21-2014 |
20140221319 | Small Molecule CD38 Inhibitors and Methods of Using Same - The invention provides methods and compositions for inhibiting CD 38 activity, and methods of treating or preventing various disorders associated with CD38 activity. | 08-07-2014 |
20140221252 | DETECTING NEOPLASM - This document relates to methods and materials for detecting premalignant and malignant neoplasms. For example, methods and materials for determining whether or not a stool sample from a mammal contains nucleic acid markers or polypeptide markers of a neoplasm are provided. | 08-07-2014 |
20140220602 | VACCINIA VIRUS POLYPEPTIDES - This document provides methods and materials related to polypeptides present in a vaccinia virus (e.g., polypeptides that can be isolated from naturally processed and presented class I polypeptides originating from vaccinia virus, a member of the Orthopoxvirus family). For example, methods for generating a vaccine comprising one or more of vaccinia virus polypeptides disclosed herein for preventing or treating Orthopoxvirus infection are provided. In addition, kits related to the use of vaccinia polypeptides are provided. | 08-07-2014 |
20140212443 | IMMUNITY TO FOLATE RECEPTORS - This document provides methods and materials related to assessing immunity to folate receptors. For example, methods and materials for assessing FRα immunity in a mammal are provided. This document also provides methods and materials related to stimulating immunity to folate receptors. | 07-31-2014 |
20140208181 | ZERO SUM SIGNALING IN A DIGITAL SYSTEM ENVIRONMENT - Zero sum signaling schemes utilize coding across data words to allow the use of single-ended buffers while mitigating simultaneous switching noise (SSN) in digital systems. Zero sum signaling may include balanced zero sum coding (target disparity=0) and nearly balanced zero sum coding (target disparity=±d). Zero sum signaling may reduce simultaneous switching noise as compared to single-ended signaling while allowing a reduction in the number of physical channels (e.g. circuit board traces) by nearly a factor of two as compared to differential signaling. | 07-24-2014 |
20140205517 | COLLECTING AND PROCESSING COMPLEX MACROMOLECULAR MIXTURES - This document provides methods and materials involved in collecting and processing complex macromolecular mixtures (e.g., stool samples). For example, stool collection devices, buffers for stabilizing nucleic acid and polypeptides present in stool, and kits for using sequence-specific capture probes (e.g., nucleic acid sequences designed to hybridize with particular target nucleic acids) to capture target nucleic acids directly from complex macromolecular mixtures (e.g., stool samples) without the need to perform prior steps to enrich, isolate, or purify the nucleic acid component are provided. | 07-24-2014 |
20140200270 | VITAMINS C AND K FOR TREATING POLYCYSTIC DISEASES - Provided herein are methods for treating, preventing, or ameliorating one or more symptoms of a polycystic disease in a subject, comprising administering to the subject a therapeutically effective amount of vitamins C and K. | 07-17-2014 |
20140189897 | TRANSGENIC ANIMALS CAPABLE OF BEING INDUCED TO DELETE SENESCENT CELLS - This document relates to methods and materials involved in the removal of senescent cells within a mammal. For example, transgenic non-human animals that can be induced to delete senescent cells are provided. | 07-03-2014 |
20140188085 | Hemostatic Devices and Methods For Use Thereof - Materials and methods for reducing or preventing bleeding and associated side effects during and after percutaneous medical procedures. | 07-03-2014 |
20140179605 | NATRIURETIC POLYPEPTIDE DELIVERY SYSTEMS - This document provides natriuretic polypeptide delivery systems. For example, methods and materials related to natriuretic polypeptide delivery systems, methods and materials related to the use of such delivery systems to deliver natriuretic polypeptides to a mammal over a pro-longed period of time (e.g., weeks to months), and methods and materials related to treating heart failure conditions are provided. | 06-26-2014 |
20140178486 | CANCER TREATEMENTS - This document provides methods and materials related to treating cancer (e.g., skin cancer). For example, methods and materials relating to the use of a composition containing albumin-containing nanoparticle/antibody complexes (e.g., Abraxane®/anti-VEGF polypeptide antibody complexes) to treat cancer (e.g., skin cancer) are provided. | 06-26-2014 |
20140148501 | DNA APTAMERS FOR PROMOTING REMYELINATION - Materials and methods related to using multimeric DNA aptamers to treat demyelinating diseases are provided herein. | 05-29-2014 |
20140141020 | ANTI-CD3 THERAPIES - This document provides methods and materials related to anti-CD3 therapies. For example, anti-CD3γε antibody preparations as well as methods and materials for using anti-CD3γε antibody preparations to reduce a T cell-mediated immune response within a mammal are provided. | 05-22-2014 |
20140136467 | METHODS AND MATERIALS FOR PROVIDING A PROGNOSTIC SCORING SYSTEM FOR THE DEVELOPMENT OF PROSTHETIC JOINT INFECTION - This document provides methods and materials for providing a scoring system to prognose the development of prosthetic joint infection (PJI). For example, a prognostic scoring system as well as methods for making and using a prognostic scoring system for the development of PJI to assist clinicians in implementing intervention or early diagnostic strategies are provided. | 05-15-2014 |
20140127666 | GALVANIC VESTIBULAR STIMULATION SYSTEM AND METHOD OF USE FOR SIMULATION, DIRECTIONAL CUEING, AND ALLEVIATING MOTION-RELATED SICKNESS - The present invention relates to systems and techniques for stimulating a user. For example, materials and methods for manipulating nystagmus and the related vestibular system with coupling of galvanic vestibular stimulation (GVS) and visual cueing are provided herein. Use of GVS within the present invention may be applied to simulation, alleviating motion sickness, and directional cueing of a user to a precise target location. | 05-08-2014 |
20140107524 | NEUROMUSCULAR MONITORING DISPLAY SYSTEM - Disclosed herein is a system for displaying a degree of neuromuscular block in a patient. An example system can include: a display unit having a graphical user interface (GUI); a processor; and a memory. The system can be configured to: receive data in response to a pattern of stimuli applied to the patient according to a stimulation protocol; determine the degree of neuromuscular block based on the received data; display a numerical representation corresponding to the degree of neuromuscular block; display a graphical representation corresponding to the degree of neuromuscular block and display a timer related to the stimulation protocol. The numerical and graphical representations can be displayed in first and second regions of the GUI, respectively. Additionally, a display color of at least a portion of the first region, the numerical and graphical representations can be configured to dynamically change based on the degree of neuromuscular block. | 04-17-2014 |
20140105972 | PREVOTELLA HISTICOLA PREPARATIONS AND THE TREATMENT OF AUTOIMMUNE CONDITIONS - This document provides methods and materials related to | 04-17-2014 |
20140104575 | QUANTIFYING OCULAR COUNTER ROLL - This document provides methods and materials for quantifying ocular counter roll and detecting vestibular otolith damage. For example, devices for quantifying ocular counter roll, methods of making devices for quantifying ocular counter roll, and methods for using a device to quantify (e.g., quantify indirectly) ocular counter roll are provided. | 04-17-2014 |
20140100460 | VEIN CLOSURE AND INJECTION KITS AND METHODS - Kits, apparatus, devices and methods for treating varicose veins caused by an incompetent venous junction (e.g., the saphenofemoral and/or saphenopopliteal junctions) are disclosed. The kits may include a sheath, a vein closure device, and an injection device. Alternatively, a vein closure device may include an integral injection channel and injection device. Methods may include injecting a vein with a sclerosing agent through a needle that extends in a direction that is not aligned with a longitudinal axis of a sheath or shaft. | 04-10-2014 |
20140088001 | METHODS FOR DIAGNOSING ORGAN SPECIFICITY OF GLUCOSE INTOLERANCE - The present application pertains to a technique useful for the differentiation and diagnosis of organ specificity of hyperglycemia and glucose intolerance in type 2 diabetes, pre-diabetes or populations with risk to develop type 2 diabetes. | 03-27-2014 |
20140066688 | BRACHYTHERAPY AND BUTTRESS ELEMENT CO-DELIVERY - Brachytherapy delivery devices and buttress elements are described herein, along with methods of assembling the brachytherapy devices and the buttress elements for co-delivery of the brachytherapy delivery devices and buttress elements are described herein. | 03-06-2014 |
20140066480 | METHODS AND MATERIALS FOR ASSESSING RESPONSIVENESS TO LENALIDOMIDE, THALIDOMIDE, AND/OR OTHER THALIDOMIDE ANALOGS - This document provides methods and materials related to assessing responsiveness to lenalidomide, thalidomide, and/or other IMiDs (structural and functional analogues of thalidomide that represent a promising new class of immunomodulators). For example, methods and materials for using CRBN levels to determine whether or not cancer cells (e.g., multiple myeloma cells) are susceptible to lenalidomide, thalidomide, and/or other IMiDs are provided. | 03-06-2014 |
20140066367 | SUBCUTANEOUS DELIVERY OF A LONG-ACTING NATRIURETIC PEPTIDE - This document provides methods and material related to natriuretic polypeptides. For example, substantially pure polypeptides having a natriuretic peptide activity, nucleic acids encoding polypeptides having a natriuretic peptide activity, host cells containing such nucleic acids, and methods for inducing a natriuretic or diuretic activity within a mammal are provided. | 03-06-2014 |
20140066323 | CANCER DIAGNOSTICS USING BIOMARKERS - Disclosed herein, in certain instances, are methods, systems and kits for the diagnosis, prognosis and determination of cancer progression of a cancer in a subject. Further disclosed herein, in certain instances, are methods, systems and kits for determining the treatment modality of a cancer in a subject. The methods, systems and kits comprise expression-based analysis of biomarkers. Further disclosed herein, in certain instances, are probe sets for use in assessing a cancer status in a subject. | 03-06-2014 |
20140065620 | NUCLEIC ACIDS FOR DETECTING BREAST CANCER - This document provides methods and materials involved in detecting breast cancer. For example, nucleic acids for detecting gene rearrangements (e.g., translocations) associated with breast cancer as well as methods and materials for detecting breast cancer are provided. | 03-06-2014 |
20140065167 | HUMAN IgM ANTIBODIES, AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF PARTICULARLY IN THE CENTRAL NERVOUS SYSTEM - Antibodies, particularly human antibodies, are disclosed having activity in treatment of demyelinating diseases and diseases of the central nervous system. Neuromodulatory agents are provided comprising a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, and active fragments, monomers and combinations thereof having one or more of the following characteristics: capable of inducing remyelination; binding to neural tissue; promoting Ca | 03-06-2014 |
20140058282 | SYSTEM AND METHOD FOR GASTRO-INTESTINAL ELECTRICAL ACTIVITY - A gastro-electrical activity mapping system and method may comprise a catheter insertable through a natural orifice into the gastro-intestinal (GI) tract and comprising an array of electrodes for contacting an interior surface of a section of the GI tract to detect electrical potentials at multiple electrodes, and comprises a signal analysis and mapping system arranged to receive and process electrical signals from multiple electrodes of the array and spatially map GI smooth muscle electrical activity as an activation time map, a velocity map, or an amplitude map, which may be in the form of contour plots and may be mapped on an anatomical computer model of at least the section of the GI tract and may be animated. | 02-27-2014 |
20140057262 | METHODS AND MATERIALS FOR USING THE CONTENTS OF PHAGOCYTES TO DETECT NEOPLASMS - This document provides methods and materials related to detecting premalignant or malignant neoplasms (e.g., colorectal and pancreatic cancer). For example, methods and materials for assessing the contents of phagocytes for the presence of one or more biological markers (e.g., Alu repeats or methylated nucleic acid) of premalignant or malignant neoplasms are provided. | 02-27-2014 |
20140056909 | TREATING CANCER - This document relates to methods and materials involved in treating cancer (e.g., melanoma). For example, methods and materials involved in using an anti-chronic inflammation treatment (e.g., chemotherapy) in combination with a cancer treatment agent (e.g., a cancer vaccine) to treat cancer are provided. | 02-27-2014 |
20140051185 | MARKERS FOR PREECLAMPSIA - This document provides methods and materials related to determining whether or not a pregnant mammal (e.g., a pregnant human) has preeclampsia. For example, methods and materials related to the use of urinary podocytes to determine whether or not a pregnant human has preeclampsia are provided. | 02-20-2014 |
20140050752 | VACCINIA VIRUS POLYPEPTIDES - This document provides methods and materials related to polypeptides present in a vaccinia virus (e.g., membrane proteins such as vaccinia virus B5R, L1R, A33R, or A27L polypeptides). For example, methods for generating a vaccine comprising one or more of vaccinia virus polypeptides disclosed herein for preventing or treating Orthopoxvirus infection are provided. In addition, kits related to the use of vaccinia polypeptides are provided. | 02-20-2014 |
20140039174 | RIBONUCLEIC ACID BINDING MOTIF PROTEIN 20 SEQUENCE VARIANTS - This document relates to methods and materials for using nucleic acid and amino acid sequence variants of ribonucleic acid binding motif protein 20 (RBM20). For example, methods and materials for using nucleic acid sequence variants and/or their corresponding amino acid variants of RBM20 that are associated with dilated cardiomyopathy to identify mammals (e.g., humans) at risk of having dilated cardiomyopathy that is likely to progress to heart failure are provided. | 02-06-2014 |
20140030743 | MARKERS FOR PREECLAMPSIA - This document provides methods and materials related to determining whether or not a pregnant mammal (e.g., a pregnant human) has preeclampsia. For example, methods and materials related to the use of urinary podocytes to determine whether or not a pregnant human has preeclampsia are provided. | 01-30-2014 |
20140030262 | MATERIALS AND METHODS FOR EVALUATING AND TREATING NEUROMYELITIS OPTICA (NMO) - The invention provides prognostic methods for evaluating the severity of NMO and NMO-associated diseases as well as methods of treating NMO and NMO-associated diseases. | 01-30-2014 |
20140026894 | NECK PAIN RELIEVING DEVICES - This document provides methods and materials related to relieving neck pain. For example, neck pain relieving devices as well as methods for making and using neck pain relieving devices to provide relief from chronic or acute neck pain by providing support to the back of the head are provided. | 01-30-2014 |
20140024029 | METHODS FOR SELECTING MEDICATIONS FOR TREATING PATIENTS HAVING ATTENTION-DEFICIT HYPERACTIVITY DISORDER - Methods for selecting a medication for a patient are described that include determining the patient's genotype for a panel of genes, identifying a phenotype associated with the genotype for each gene, and selecting the medication based on the phenotype. | 01-23-2014 |
20140012388 | RADIAL HEAD PROSTHESES AND TRIALS - Radial head prostheses and trialing devices. A radial head prosthesis includes a head component and a stem component, and may include an intermediate component. The head component may be offset from the stem component. The head component includes a bearing surface having an axis of rotation, which may be radially and/or angularly offset from the central longitudinal axis of the stem component. A radial head trialing device may include cutting edges for resection of a distal radius. Another trialing device may allow for adjusting the radial offset and/or angular position of a trial head component from a trial stem component. | 01-09-2014 |
20140005358 | NATRIURETIC POLYPEPTIDES | 01-02-2014 |
20130345142 | DETECTING AND TREATING DEMENTIA - This document relates to methods and materials for detecting mutations that can be linked to dementia. For example, methods and materials for detecting one or more mutations within PGRN nucleic acid are provided. This document also provides methods and materials for detecting the level of progranulin expression. In addition, this document relates to methods and materials for treating mammals having a neurodegenerative disorder (e.g., dementia). For example, methods and materials for increasing PGRN polypeptide levels in mammals are provided, as are methods and materials for identifying agents that can be used to increase PGRN polypeptide levels in mammals. | 12-26-2013 |
20130338741 | GASTRODUODENAL BALLOON TUBES AND METHODS FOR USE IN LOCALIZED HYPOTHERMIA - Materials and methods for producing localized hypothermia in a patient (e.g., for treatment of acute pancreatitis and pancreatic cancer). | 12-19-2013 |
20130338681 | ADJUSTABLE FASTENING OR CONSTRICTING DEVICES - This document relates to methods and materials involved in fastening or constricting. For example, devices (e.g., adjustable vascular pedicle constricting devices) configured to allow a user (e.g., a surgeon) to apply a band element at least partially around a desired structure (e.g., tissue such as a vascular pedicle) in a manner that allows the degree of constriction to be adjustable are provided. | 12-19-2013 |
20130330329 | B7-H7 ANTIBODIES AND METHOD OF USE - The invention provides novel polypeptides useful for co-stimulating T cells, isolated nucleic acid molecules encoding them, vectors containing the nucleic acid molecules, and cells containing the vectors. Also included are methods of making and using these co-stimulatory polypeptides. | 12-12-2013 |
20130323262 | METHODS AND MATERIALS FOR TREATING INFLAMMATORY CONDITIONS - Methods and kits for treating inflammatory conditions are described that include modulating kallikrein 6 protease activity. | 12-05-2013 |
20130317390 | CYTOLOGICAL SAMPLE ACQUISITION DEVICE AND METHOD - A tissue collection device and method. One embodiment of the device includes a body formed by an elongated member, a pair of inflatable balloons at spaced-apart locations on the body, and one or more collection structures on the body. Inflation lumens extending through the body and coupled to the balloons cause the balloons to move between collapsed and expanded states. The collection structures collect a tissue sample from a collection region between the balloons. In another embodiment the collection structures include one or more of an irrigation lumen and an aspiration lumen having one or more ports opening into the collection region. | 11-28-2013 |
20130315926 | METHODS AND MATERIALS FOR MODULATING RESISTANCE TO APOPTOSIS - This document provides methods and materials involved in modulating a cell's ability to be resistant to apoptosis. For example, methods and materials for exposing cells to KLK6 polypeptides, or increased KLK6 polypeptide activity, to promote resistance to apoptosis are provided. In addition, methods and materials for reducing the ability of KLK6 polypeptides to promote resistance to apoptosis are provided. | 11-28-2013 |
20130315905 | B7-H5, A Costimulatory Polypeptide - B7-H5 costimulatory polypeptides, nucleic acids encoding such polypeptides, and methods for using the polypeptides and nucleic acids to enhance a T cell response are provided herein. | 11-28-2013 |
20130311202 | Methods for Selecting Medications - The invention provides a computer program product for selecting and administering a psychotropic medication for a patient. The computer program product utilizes a combination of genotype and phenotype information to provide the user with accurate guidance regarding the appropriate medication and its use. | 11-21-2013 |
20130303454 | LONG ACTING ATRIAL NATRIURETIC PEPTIDE (LA-ANP) AND METHODS FOR USE THEREOF - Materials and Methods related to making and using natriuretic polypeptides having a mutation that results in an extended carboxy terminus. | 11-14-2013 |
20130302808 | PREDICTING CANCER OUTCOME - This document provides methods and materials related to assessing prostate cancer in mammals. For example, methods and materials for using ERG expression levels and TOP2A expression levels to identify mammals (e.g., male human patients) as being susceptible to a poor prostate cancer outcome are provided. | 11-14-2013 |
20130296654 | TRANSORAL RETRACTOR FOR ROBOTIC SURGERY - A transoral retractor in accordance with one embodiment of the invention includes a handle, a retractor blade mount attached to the handle, a frame and a pivot mechanism to pivotally mount the frame to the handle. In another embodiment the frame includes side members and is configured with the side members at transverse locations that will be near or beyond the side of the patient's head. The frame and/or pivot mechanism are configured to locate a plane of the frame generally at or near the plane of the patient's oral commissaries, with the side members located below the plane of the oral commissaries. | 11-07-2013 |
20130281377 | TREATING MULTIPLE MYELOMA - This document relates to methods and materials for treating multiple myeloma. For example, methods and materials for using albumin-bound paclitaxel composition (e.g., Abraxane®, a paclitaxel albumin-stabilized nanoparticle formulation) to treat multiple myeloma are provided. | 10-24-2013 |
20130267685 | B7-H3 and B7-H4, Novel Immunoregulatory Molecules - The invention provides novel B7-H3 and B7-H4 polypeptides useful for co-stimulating T cells, isolated nucleic acid molecules encoding them, vectors containing the nucleic acid molecules, and cells containing the vectors. Also included are methods of making and using these co-stimulatory polypeptides. | 10-10-2013 |
20130251736 | METHODS FOR REDUCING GRANULOMATOUS INFLAMMATION - This document provides methods and materials for reducing bacterial induced granulomatous inflammation in a mammal using agents that reduce B7-H1 expression or activity. | 09-26-2013 |
20130251681 | VESICULAR STOMATITIS VIRUSES - This document provides methods and materials related to vesicular stomatitis viruses. For example, vesicular stomatitis viruses, nucleic acid molecules encoding VSV polypeptides, methods for making vesicular stomatitis viruses, and methods for using vesicular stomatitis viruses to treat cancer are provided. | 09-26-2013 |
20130247921 | PORTAL FOR MEDICAL INSTRUMENTS - This document provides methods and materials related to portals that can be used to create a channel through a surgical drape without compromising the sterile operating field. For example, a portal provided herein can include an applicator frame and sheath (e.g., flexible sheath) that is capable of creating a channel into a sterile operating field so that a device, whether sterile or not, can be used at the time of surgery without compromising the sterility of the surgical field. | 09-26-2013 |
20130244902 | EARLY DETECTION OF PANCREATIC CANCER - This document provides methods and materials involved in the early detection of pancreatic cancer. For example, this document provides methods and materials for assessing nucleic acid obtained from a blood sample of a human for a CpG methylation site profile that, at least in part, indicates that the human has pancreatic cancer. | 09-19-2013 |
20130244335 | VITAMIN D DEFICIENCIES - Methods for determining the amount of vitamin D compounds in a sample are provided. The methods can employ LC-MS/MS techniques and optionally the use of deuterated internal standards. Methods for diagnosing vitamin D deficiencies are also provided. | 09-19-2013 |
20130244235 | METHODS AND MATERIALS FOR NONINVASIVE DETECTION OF COLORECTAL NEOPLASIA ASSOCIATED WITH INFLAMMATORY BOWEL DISEASE - The present invention provides methods and materials related to the detection of colorectal neoplasia (CRN) associated with inflammatory bowel disease (IBD). The present invention provides markers specific for colorectal neoplasia associated with inflammatory bowel disease in or associated with a subject's stool sample. In particular, the present invention provides methods and materials for identifying mammals (e.g., humans) having colorectal neoplasia associated with inflammatory bowel disease by detecting the presence and level of indicators of colorectal neoplasia such as, for example, epigenetic alterations (e.g., DNA methylation) (e.g., CpG methylation) (e.g., CpG methylation in coding or regulatory regions of BMP3, NDRG4, vimentin, EYA4) in DNA from a stool sample obtained from the mammal. | 09-19-2013 |
20130243752 | RECOMBINANTLY PRODUCED ANTIBODY - An antibody capable of potentiating immune responses and modifying existing states of immune responsiveness is described, as is the sequence of the antibody. Also described are compositions containing the antibody, as well as methods for using the antibody and the compositions to enhance immune responses, to enhance DC function, to modify an existing state of immune responsiveness, to immunize individuals, or to treat or inhibit conditions such as allergic asthma. | 09-19-2013 |
20130237590 | ASSESSING THYROID NEOPLASMS - This document provides methods and materials involved in assessing thyroid neoplasms. For example, methods and materials for using microRNA (miR) levels (e.g., miR122 levels) to determine whether a thyroid neoplasm (e.g., a follicular thyroid neoplasm) is benign or malignant as well as methods and materials for using miR levels (e.g., miR122 levels) to determine whether a malignant thyroid cancer patient is likely to have a favorable or unfavorable outcome are provided. This document also provides methods and materials involved in treating cancer. | 09-12-2013 |
20130236486 | IMMUNOGENIC VACCINE - A glycolipopeptide comprising a carbohydrate component, a lipid component, and a MUC1 peptide component that induces both a humoral and a cellular immune response for use as a therapeutic or prophylactic vaccine. | 09-12-2013 |
20130224312 | METHODS AND MATERIALS FOR ASSESSING RESPONSIVENESS TO PARP INHIBITORS AND PLATINATING AGENTS - This document provides methods and materials involved in assessing responsiveness to PARP inhibitors and platinating agents. For example, methods and materials for using levels of non-homologous end-joining pathway members (e.g., artemis mRNA or polypeptide levels, Ku80 mRNA or polypeptide levels, or DNA-PKcs mRNA or polypeptide levels) to determine if cancer cells that are homologous recombination-deficient are likely to be susceptible or resistant to PARP inhibitors and platinating agents are provided. | 08-29-2013 |
20130219536 | LRRK2 POLYNUCLEOTIDES AND TRANGENIC ANIMALS - A polynucleotide consisting of the base sequence of SEQ ID NO:2, or a complementary strand thereto, wherein the X is one of the group being defined by the bases A, C or T. A primer and a probe specific for that polynucleotide, wherein the primer and/or probe contains at least 10 consecutive nucleotides, and finally use of the probe for proving parkinsonism inheritance. | 08-22-2013 |
20130217731 | CD38 AND OBESITY - This document provides methods and materials relating to obesity. For example, methods and materials related to treating obesity and identifying agents having the ability to treat obesity are provided. | 08-22-2013 |
20130211537 | MEDICAL DEVICES INCLUDING DUPLEX STAINLESS STEEL - Medical devices, such as endoprostheses, and methods of making the devices are disclosed. The endoprostheses comprise a tubular member capable of maintaining patency of a bodily vessel. The tubular member includes a duplex stainless steel (e.g., 2205 stainless steel), which may be magnetized. | 08-15-2013 |
20130211220 | ESTIMATION OF INSULIN SENSITIVITY FROM CGM AND SUBCUTANEOUS INSULIN DELIVERY IN TYPE 1 DIABETES - In a method of determining insulin sensitivity in a patient, glucose level is sensed continuously. A first area under the curve representing the glucose level over time is calculated. An amount of insulin that has been administered to the patient is sensed. An estimation of insulin on board the patient is calculated based on the glucose level and the amount of insulin administered to the patient. A second area under the curve representing the insulin on board over time is calculated. Patient data indicative of at least one patient physical parameter is received. Information indicative of amount of glucose ingested by the patient during a meal is received. An insulin sensitivity output indicative of ability of insulin to stimulate glucose utilization and inhibit glucose production in the patient based on the first and second area under the curve, the patient data and the meal information is generated. | 08-15-2013 |
20130204155 | Anesthesia Monitoring Systems and Methods of Monitoring Anesthesia - Provided are systems, devices and methods for monitoring anesthesia. For example, the methods, devices and systems are optionally used to assess neuromuscular blockade in a subject who has received a muscle relaxant (NMBA) agent. | 08-08-2013 |
20130202619 | METHODS AND MATERIALS FOR REDUCING LIVER FIBROSIS - This document relates to methods and materials for treating diseases or disorders that are caused by or associated with lumican deposition (e.g., liver fibrosis). For example, methods and materials for reducing liver fibrosis by reducing lumican expression or activity within a mammal (e.g., a human) are provided. | 08-08-2013 |
20130202292 | POWER RECAPTURE IN AN OPTICAL COMMUNICATIONS SYSTEM - In an n-node optical communications system, energy harvesting photodetectors at each node receive extraneous electromagnetic wavelengths that are not used for communication or other purposes by the associated node. The energy harvesting photodetectors convert the unused electromagnetic energy into reusable electrical energy. The harvested electrical energy may be used as auxiliary power at the node or elsewhere in the communication system, or stored in a battery, capacitor, or other energy storage device. The system may be used in an “all-to-all” broadcast and select communication scheme or in some other broadcast and select interconnect system that has extraneous wavelengths at node receivers. | 08-08-2013 |
20130202170 | AUTOMATED VASCULAR REGION SEPARATION IN MEDICAL IMAGING - A system and/or method automatically identifies one or more vascular regions in a medical image or set of medical images. For example, the system/method may automatically identify vascular structures as belonging to the left carotid, right carotid, and/or basilar vascular regions in the head. The system/method takes as input the medical image(s) and automatically identifies one or more vascular regions. The system/method may also automatically generate MIP renderings of the identified region or regions. | 08-08-2013 |
20130191931 | FUMARYLACETOACETATE HYDROLASE (FAH)-DEFICIENT PIGS AND USES THEREOF - Described herein is the generation of Fah | 07-25-2013 |
20130191097 | ERYTHROPOIETIC STIMULATING AGENT (ESA) DOSAGE DETERMINATION - An Erythropoietic Stimulating Agent (ESA) dosing system/method determines patient-specific ESA therapies for patients affected by insufficient hemoglobin production that may benefit from ESA treatment. The ESA dosing system includes a model that represents a process by which red blood cells are produced in humans. The model may include one or more parameters, the values of which are patient-specific. The model takes into account patient-specific historical hemoglobin (Hgb) data and corresponding historical ESA dosage data to estimate the patient-specific values of the model parameters, and determines a target therapeutic dose of the ESA that may maintain the patient's Hgb within a target range. | 07-25-2013 |
20130190860 | PERCUTANEOUSLY DELIVERABLE VALVES - This document provides methods and materials related to providing a mammal with a replacement valve (e.g., a synthetic or artificial heart valve). For example, synthetic or artificial heart valve that can be delivered in a minimally invasive manner are provided. | 07-25-2013 |
20130184635 | OBESITY TREATMENT AND DEVICE - A method and apparatus are disclosed for treating obesity includes an artificial fistula created between gastrointestinal organs such as between the stomach and the colon. The method includes selecting an implant comprising a passageway having an internal lumen with an inlet end and an outlet end. The passageway is positioned passing through a first wall of first gastrointestinal organ (for example, passing through the wall of the stomach) and a second wall of a second gastrointestinal organ (for example, passing through the wall of the large intestine) with the inlet end disposed within an interior of the first gastrointestinal organ and with the outlet disposed within an interior of the second gastrointestinal organ. | 07-18-2013 |
20130184607 | METHODS AND MATERIALS FOR CALIBRATING A CALORIC TEST - This document provides methods and materials for calibrating a caloric assay. For example, caloric calibration devices and methods for using caloric calibration devices to calibrate a caloric test are provided. | 07-18-2013 |
20130184599 | NON-INVASIVE MONITORING OF PHYSIOLOGICAL CONDITIONS - This document provides methods and materials related to the non-invasive measurement of analytes in blood. | 07-18-2013 |
20130173177 | NUCLEIC ACID SEQUENCE ANALYSIS - This document provides materials and methods involved in nucleic acid sequence analysis. For example, methods and materials for distinguishing sequencing errors (e.g., sequencing and/or PCR artifacts) from true polymorphic sequence variations (e.g., single-nucleotide polymorphisms, sequence insertions, sequence deletions, or combinations thereof) are provided. In addition, methods and materials for determining homozygosity or heterozygosity are provided. | 07-04-2013 |
20130171647 | PREDICTING RESPONSES TO ANDROGEN DEPRIVATION THERAPY - This document provides methods and materials for identifying prostate cancer patients likely to respond to an androgen deprivation therapy. For example, methods and materials for identifying a prostate cancer patient likely to respond to an androgen deprivation therapy based at least in part on the presence of a genetic variation in a TMRT11 nucleic acid are provided. This document also provides methods and materials for identifying prostate cancer patients likely to survive prostate cancer related death for a short or long period of time. For example, methods and materials for identifying a prostate cancer patient likely to survive prostate cancer related death for a short or long period of time based at least in part on the presence of a genetic variation in a UGT1A3 nucleic acid, a UGT1A7 nucleic acid, and/or a UGT1A10 nucleic acid are provided. | 07-04-2013 |
20130171639 | MATERIALS AND METHODS FOR DIAGNOSIS, PROGNOSIS, MONITORING OF RECURRENCE, AND ASSESSMENT OF THERAPEUTIC/PROPHYLACTIC TREATMENT OF PANCREATOBILIARY CANCER - A method of detecting high-grade dysplasia, pancreatobiliary cancer, or metastatic cancer to the pancreatobiliary tract or inferring an increased risk thereof, comprising obtaining a sample of pancreatobiliary cells from a patient with a set of detectably labeled probes comprising a locus-specific probe for MCL1 (myeloid cell leukemia sequence 1), a locus-specific probe for EGFR (epidermal growth factor receptor), a locus-specific probe for MYC, and a locus-specific probe for P16 under hybridization conditions and determining the presence of chromosomal abnormalities; a set of probes comprising a locus-specific probe for MCL1, a locus-specific probe for EGFR, a locus-specific probe for MYC, and a locus-specific probe for P16; and a kit comprising the set of probes and instructions for detecting high-grade dysplasia, pancreatobiliary cancer, or metastatic cancer to the pancreatobiliary tract, or inferring an increased risk thereof, in a patient. | 07-04-2013 |
20130158389 | MULTI-SEGMENT SLANT HOLE COLLIMATOR SYSTEM AND METHOD FOR TUMOR ANALYSIS IN RADIOTRACER-GUIDED BIOPSY - A system and method for molecular breast imaging (MBI) provides enhanced tumor analysis and, optionally, a real-time biopsy guidance. The system includes a detector head including a gamma ray detector and a multisegment collimator in a collimator frame. The collimator contains multiple collimation sections that have respectively different collimating characteristic and that are individually repositionable with respect to the detector. An image of the tissue acquired with the system may include spatially separate image portions containing image information about the same portion of the imaged tissue. A system of mounting the multisegment collimator in the detector head includes a collimator tray that is laterally moveable within the frame and/or slidable in and out of the frame. | 06-20-2013 |
20130144190 | SLEEP APNEA DETECTION SYSTEM - This document provides methods and materials (e.g., systems) related to assessing sleep conditions (e.g., sleep apnea). | 06-06-2013 |
20130143820 | DIURETIC AND NATRIURETIC POLYPEPTIDES - This document provides diuretic and natriuretic polypeptides. For example, this document provides polypeptides having diuretic and/or natriuretic activities. In some cases, a polypeptide provided herein can have diuretic and natriuretic activities, while lacking the ability to lower blood pressure. This document also provides methods and materials for inducing diuretic and/or natriuretic activities within a mammal. | 06-06-2013 |
20130143232 | METHODS FOR THE DETECTION AND MONITORING OF ACUTE MYOCARDIAL INFARCTION - Disclosed herein are methods of detecting and/or prognosing myocardial infarction by detecting a proteolytic fragment of caspase-3 such as the p17 fragment or the p12 fragment. The myocardial infarction can be STEMI or NSTEMI. | 06-06-2013 |
20130143196 | METHODS AND MATERIALS FOR PROLONGING USEFUL STORAGE OF RED BLOOD CELL PREPARATIONS AND PLATELET PREPARATIONS - This document provides methods and materials for enhancing the storage capabilities of red blood cell preparations. For example, methods and materials for using CO | 06-06-2013 |
20130136730 | METHODS AND MATERIALS FOR REDUCING BIOFILMS - This document provides methods and materials related to reducing biofilms. For example, enzymes (e.g., glycosyl hydrolases), nucleic acid molecules encoding enzymes, host cells containing nucleic acid encoding enzymes, and methods for using enzymes to reduce biofilms and infections associated with biofilms are provided. | 05-30-2013 |
20130131827 | METHODS AND MATERIALS FOR REPLACING A CIRCUMFERENTIAL SEGMENT OF AN ESOPHAGUS - This document provides methods and materials that can be used to replace a circumferential segment of an esophagus. For example, methods and materials that can be used to provide a tubular connection from one stump end of an esophagus to another stump end of the esophagus are provided. | 05-23-2013 |
20130131823 | ACETABULAR CUP PROSTHESIS - Provided are acetabular cup implant assemblies that can be used in hip replacement surgery. Example assemblies comprise a shell and a liner. The liner can be positioned within a shell. Optionally, the liner can be rotated relative to the shell until the liner is seated in the shell in a position where the liner and shell can be secured to one another. Waveform-shaped features of the shell and liner can guide the relative rotation of the liner and shell. Also provided are methods of seating a liner in shell of an acetabular cup implant assembly | 05-23-2013 |
20130123335 | IDH1 AND IDH2 MUTATIONS IN CHOLANGIOCARCINOMA - This document relates to methods and materials involved in assessing isocitrate dehydrogenase 1 (IDH1) or isocitrate dehydrogenase 2 (IDH2) mutations in a mammal (e.g., human). For example, this document provides methods and materials for diagnosis, characterization, determining prognosis, and treatment of cholangiocarcinoma tumor in a mammal. | 05-16-2013 |
20130122522 | ASSESSING MAMMALS FOR VASCULAR DISEASES AND VALVULAR DISEASES - This document provides methods and materials related to assessing mammals for vascular disease. This document also provides methods and materials related to assessing mammals for valvular disease. For example, methods and materials for assessing mammals for vascular disease using elevated levels of endothelial progenitor cells expressing a bone-related polypeptide (e.g., an osteocalcin polypeptide) as markers are provided. | 05-16-2013 |
20130122021 | B7-H3 IN CANCER - Methods of determining the prognosis of a subject with cancer and determining risk of cancer progression by assessing expression of B7-H3. Methods of reducing B7-H3 levels and/or activity. | 05-16-2013 |
20130111614 | METHODS AND MATERIALS FOR REDUCING CARDIAC XENOGRAFT REJECTION | 05-02-2013 |
20130110042 | Hemostatic Devices and Methods for Use Thereof | 05-02-2013 |
20130103425 | IMAGING UTILITY SCORE - An electronically based utility rating system and/or method measures the appropriateness of computerized physician order entry (CPOE) requests for medical imaging examinations. The so-called “imaging utility score” or simply, “u-score” may provide comparative data to help combat inappropriate medical imaging examinations, review resource utilization, and provide opportunities for medical education. | 04-25-2013 |
20130103415 | IMAGING UTILITY SCORE - An electronically based utility rating system and/or method measures the appropriateness of computerized physician order entry (CPOE) requests for medical imaging examinations. The so-called “imaging utility score” or simply, “u-score” may provide comparative data to help combat inappropriate medical imaging examinations, review resource utilization, and provide opportunities for medical education and research. | 04-25-2013 |
20130101653 | METHODS AND MATERIALS FOR REDUCING THE RISK OF INFECTIONS - This document relates to methods and materials for reducing the risk of infection after a shoulder surgery or medical procedure. For example, this document relates to methods and materials for using a topical composition containing clindamycin or erythromycin to reduce the risk of or to prevent infection associated with shoulder surgeries or medical procedures. | 04-25-2013 |
20130096692 | NON-CIRCULAR ESOPHAGEAL STENTS AND DELIVERY SYSTEMS - Stents that have non-circular cross-sectional profiles and systems for delivering the stents are described herein. | 04-18-2013 |
20130085080 | PREDICTING CANCER OUTCOME - This document provides methods and materials related to assessing prostate cancer in mammals. For example, this document provides nucleic acids and polypeptides that can be analyzed to determine whether a male mammal having prostate cancer is susceptible to a good or poor outcome. | 04-04-2013 |
20130079616 | DETECTING AND TREATING NERVOUS SYSTEM DISORDERS - Some embodiments of a mapping device may be capable of passing through cerebral veins and other cerebrovascular spaces to provide electrophysiological mapping of the brain. These embodiments of the device may also be capable of providing, simultaneously or separately, ablation energy or other treatments to targeted brain tissue. In such circumstances, a user may be enabled to analyze an electrophysiological map of a patient's brain and, at the same time or within a short time period before or after the mapping process, may be enabled to apply ablation energy for treatment of a central nervous system disorder. Such treatment may be accomplished without the use of invasive surgery in which the brain is accessed through an opening in the patient's cranium. | 03-28-2013 |
20130064857 | METHODS AND MATERIALS FOR MAKING AND USING VACCINES - This document relates to methods and materials for making and using vaccines. For example, vaccine preparations (e.g., whole cell vaccines and cell lysate vaccines) that can be used to treat cancer (e.g., human ovarian cancer) are provided. | 03-14-2013 |
20130063146 | SYSTEM AND METHOD FOR CONTROLLING CALIBRATION AND DELAY PHASES OF PARALLEL, CONTRAST-ENHANCED MAGNETIC RESONANCE IMAGING - A system and method for performing parallel magnetic resonance angiography includes controlling operation of a magnetic gradient system and an RF system to perform a calibration data pulse sequence to begin acquiring calibration data for use in a parallel imaging reconstruction process after receiving an indication that the subject has received a dose of a contrast agent. The acquisition of the calibration data is discontinued before the contrast agent reaches a peak concentration within a region of interest (ROI) of the subject and operation of the magnetic gradient system and RF system is controlled to perform an imaging pulse sequence in accordance with a parallel imaging acquisition to begin acquiring image data from the ROI. The image data is reconstructed into an image of the ROI using the calibration data. | 03-14-2013 |
20130059864 | INHIBITING NEUROTRANSMITTER REUPTAKE - This document relates to compounds as well as methods and materials involved in modulating neurotransmitter reuptake. For example, compounds, methods for synthesizing compounds, and methods for inhibiting neurotransmitter reuptake are provided. | 03-07-2013 |
20130053802 | OSTOMY DEVICES - This document provides methods and materials related to ostomy devices. For example, ostomy bags or pouches that can be used to collect discharge from a temporary or permanent ostomy opening are provided. | 02-28-2013 |
20130046331 | BODY LUMEN OCCLUSION APPARATUS AND METHODS - Body lumen occlusion apparatus and methods are described. | 02-21-2013 |
20130041383 | APPARATUS AND METHODS FOR INTERNAL SURGICAL PROCEDURES - Apparatus and methods for internal surgical procedures are disclosed. The apparatus and methods may involve supporting internal body locations, creating submucosal separations (blebs), and/or for resecting mucosal tissue separated from underlying tissue by a bleb. | 02-14-2013 |
20130040398 | VITAMIN D DEFICIENCIES - Methods for determining the amount of vitamin D compounds in a sample are provided. The methods can employ LC-MS/MS techniques and optionally the use of deuterated internal standards. Methods for diagnosing vitamin D deficiencies are also provided. | 02-14-2013 |
20130034861 | EARLY MARKER OF PROTEINURIA IN PATIENTS TREATED WITH AN ANTI-VEGF TREATMENT - This document provides methods and materials related to determining whether or not a human receiving a therapy (e.g., an anti-VEGF therapy such as a bevacizumab therapy) has developed or is at risk for developing proteinuria. For example, methods and materials for detecting urinary podocytes to determine whether or not a human receiving anti-VEGF therapy has or is at risk for developing proteinuria or kidney injury are provided. | 02-07-2013 |
20130030543 | HIP IMPLANT - Provided herein are hip implant devices and related surgical methods. The hip implants and methods can optionally be used in patients of Asian descent. | 01-31-2013 |
20130030043 | TREATING GLAUCOMA, CARDIOVASCULAR DISEASES, AND RENAL DISEASES - This document provides methods and materials related to treating glaucoma, ocular hypertension, cardiovascular diseases, and renal diseases. For example, this document provides isolated nucleic acid molecules and viral vectors (e.g., lentiviral vectors) containing isolated nucleic acid molecules. Methods for reducing intraocular pressure as well as symptoms and progression of cardiovascular and renal diseases also are provided. | 01-31-2013 |
20130023484 | PERIPHERIN-SPECIFIC AUTOANTIBODIES AS A MARKER FOR NEUROLOGICAL AND ENDOCRINOLOGICAL DISEASE - The present invention provides for methods and materials for detecting a peripherin-specific autoantibody, which can be associated with neurological and endocrinological disease. | 01-24-2013 |
20130012938 | Device and Method for Treating Cardiac Disorders by Modulating Autonomic Response - A method and device for modulating the autonomic nervous system adjacent a pericardial space to treat cardiac arrhythmia includes a treatment source arranged to supply a treatment medium, a catheter having an end sized for insertion into the pericardial space, a medium delivery assembly having a distal end arranged to be positioned by the catheter into the pericardium, with the distal end of the delivery assembly comprising a delivery tip arranged to extend away from the distal end of the catheter into the pericardial space. A connector operatively couples the delivery tip of the medium delivery assembly to the treatment source, and the delivery tip of the medium delivery assembly including a plurality of delivery points for delivering the treatment medium at a plurality of treatment areas within the pericardial space. The device performs modulation or ablation of the autonomic nervous system at selected treatment areas within the pericardium. | 01-10-2013 |
20130012410 | METHODS AND MATERIALS FOR DETECTING COLORECTAL CANCER AND ADENOMA - The present invention provides methods and materials related to the detection of colorectal neoplasm-specific markers (e.g., markers associated with colorectal cancer, markers associated with adenoma) in or associated with a subject's stool sample. In particular, the present invention provides methods and materials for identifying mammals (e.g., humans) having a colorectal neoplasm by detecting the presence and level of indicators of colorectal neoplasia such as, for example, long DNA (e.g., quantified by Alu PCR) and the presence and level of tumor-associated gene alterations (e.g., mutations in KRAS, APC, melanoma antigen gene, p53, BRAF, BAT26, PIK3CA) or epigenetic alterations (e.g., DNA methylation) (e.g., CpG methylation) (e.g., CpG methylation in coding or regulatory regions of bmp-3, bmp-4, SFRP2, vimentin, septin9, ALX4, EYA4, TFPI2, NDRG4, FOXE1) in DNA from a stool sample obtained from the mammal. | 01-10-2013 |
20120327204 | ENHANCED SIGNAL NAVIGATION AND CAPTURE SYSTEMS AND METHODS - Navigation and tissue capture systems and methods for navigation to and/or capture of selected tissue using the innate electrical activity of the selected tissue and/or other tissue are described. In the context of left atrial appendage closure, the systems and methods can be used to navigate to the left atrial appendage and capture/control the appendage while a closure instrument (suture, clip, ring) is placed over the appendage and tightened down or a closure method (ablation, cryogenic procedures, stapling, etc.) is performed to close the left atrial appendage. The use of innate electrical activity for navigating devices may be used in connection with other tissues and/or areas of the body. | 12-27-2012 |
20120323219 | DELIVERING DRUGS TO DESIRED LOCATIONS WITHIN A MAMMAL - This document provides materials and methods related to delivering drugs to desired locations within a mammal. For example, materials and methods for implanting a guide wire and a drug eluting implant into a mammal are provided. | 12-20-2012 |
20120322984 | METHODS OF REDUCING TRAIL-INDUCED APOPTOSIS BY TRAIL ISOFORMS - This document provides to methods and materials related to apoptosis. For example, methods and materials for modulating apoptosis are provided. In addition, methods and materials for treating a mammal having an apoptosis-associated condition are provided. | 12-20-2012 |
20120321164 | METHODS FOR NON-LINEAR IMAGE BLENDING, ADJUSTMENT AND DISPLAY - A method for generating and adjusting an image obtained based on computed tomography data using a non-linear blending function is provided. In one embodiment of the method, first image data is obtained using a first X-ray energy, and second image data is obtained using a second X-ray image energy. An image is generated by blending the first and second image data using the non-linear function. The first X-ray energy and the second X-ray energy are different. | 12-20-2012 |
20120315273 | TREATING SKIN CANCER - This document provides methods and materials related to treating skin cancer. For example, methods and materials relating to the use of a taxane compound, an alkylating agent, and an anti-VEGF polypeptide antibody to treat skin cancer are provided. | 12-13-2012 |
20120308601 | METHODS AND MATERIALS FOR TREATING CANCER - This document provides methods and materials related to treating cancer. For example, methods and materials for using nucleic acid libraries to treat cancer are provided. | 12-06-2012 |
20120303284 | DETERMINATION OF TIMING OF CHEMOTHERAPY DELIVERY - A system and method for determination of one or more favorable time(s) for chemotherapy or other pharmacological treatment delivery analyze time-dependent fluctuations of at least one biological variable measured in blood samples obtained from clinical patients and determine one or more favorable times for the pharmacological treatment of the patient. In some examples, the biological variables are immune variables. | 11-29-2012 |
20120288956 | COLLECTING AND PROCESSING COMPLEX MACROMOLECULAR MIXTURES - This document provides methods and materials involved in collecting and processing complex macromolecular mixtures (e.g., stool samples). For example, stool collection devices, buffers for stabilizing nucleic acid and polypeptides present in stool, and kits for using sequence-specific capture probes (e.g., nucleic acid sequences designed to hybridize with particular target nucleic acids) to capture target nucleic acids directly from complex macromolecular mixtures (e.g., stool samples) without the need to perform prior steps to enrich, isolate, or purify the nucleic acid component are provided. | 11-15-2012 |
20120288535 | RARE EARTH NANOPARTICLES - This document provides methods and materials related to rare earth particles such as rare earth nanorods (e.g., inorganic lanthanide hydroxide nanorods). For example, rare earth (e.g., lanthanide) particles such as europium hydroxide nanorods, methods and materials for making rare earth particles (e.g., europium hydroxide nanorods), and methods and materials for using rare earth particles (e.g., europium hydroxide nanorods) as an imaging agent and/or to promote angiogenesis are provided. | 11-15-2012 |
20120284004 | INVERTEBRATE ACETYLCHOLINESTERASE INHIBITORS - Methods for determining invertebrate- and insect-specific, such as mosquito-specific, residues of acetylcholinesterases are provided herein. The methods can be used to design pesticides and insecticides that are specific for the invertebrate or insect (e.g., mosquito) enzymes, resulting in reduced toxicity concerns for mammals. Compositions for inhibiting invertebrate and insect (e.g., mosquito) acetylcholinesterases and methods for preparing the same are also provided. | 11-08-2012 |
20120271404 | PATIENT-SPECIFIC MODIFIABLE STENTS - Implantable stents and stent systems that include one or more features that can be selectively modified at the point of use, i.e., in the surgical suite, etc. The selectively modifiable features may take a variety of forms such as, e.g., length, the presence of flaps, voids, etc. | 10-25-2012 |
20120270197 | PHYSIOLOGY SIMULATION GARMENT, SYSTEMS AND METHODS - Physiology simulation garments, systems including physiology simulation garments, and methods of using the same are described herein. | 10-25-2012 |
20120230989 | METHODS AND MATERIALS FOR TREATING RENAL CELL CARCINOMA - This document provides methods and materials related to treating renal cell carcinoma. For example, methods and materials for assessing a cancer patient (e.g., a renal cell carcinoma patient) for tumor or peritumoral tissue containing CD14 | 09-13-2012 |
20120225043 | Enhancement of Immune Responses By 4-1BB-Binding Agents - This invention features methods of enhancing immune responses in mammalian subjects and in vitro methods of enhancing the response of a T cell. Also embodied by the invention are methods of receiving and preventing the induction of energy in T cells. | 09-06-2012 |
20120221036 | ISOMARK TATTOOING DEVICES - A device and method for marking a treatment isocenter on a patient's body. One embodiment includes a base including alignment indicia, a marker disposed over the base and positioned relative to the indicia for marking the isocenter on the patient's body and an actuator for actuating the marker and causing a mark indicating the isocenter to be made on the patient's body. The actuator can include a button and a spring coupled to the marker. Compressing the actuator causes the marker to travel through an ink well prior to piercing the patient's skin. | 08-30-2012 |
20120220890 | DETECTING AND TREATING NERVOUS SYSTEM DISORDERS - Some embodiments of a mapping device may be capable of passing through cerebral veins and other cerebrovascular spaces to provide electrophysiological mapping of the brain. These embodiments of the device may also be capable of providing, simultaneously or separately, ablation energy or other treatments to targeted brain tissue. In such circumstances, a user may be enabled to analyze an electrophysiological map of a patient's brain and, at the same time or within a short time period before or after the mapping process, may be enabled to apply ablation energy for treatment of a central nervous system disorder. Such treatment may be accomplished without the use of invasive surgery in which the brain is accessed through an opening in the patient's cranium. | 08-30-2012 |
20120220665 | Inhibiting Neurotransmitter Reuptake - This document relates to compounds as well as methods and materials involved in modulating neurotransmitter reuptake. For example, compounds, methods for synthesizing compounds, and methods for inhibiting neurotransmitter reuptake are provided. | 08-30-2012 |
20120218051 | ELECTRICAL CIRCUIT SIGNAL CONNECTION SYSTEM - A termination block for connecting a first signal device and a second signal device. The termination block includes a housing, first and second connectors, and an electrical circuit having passive elements that connect the first and second connectors and provide impedance matching. | 08-30-2012 |
20120213833 | PREVOTELLA HISTICOLA PREPARATIONS AND THE TREATMENT OF AUTOIMMUNE CONDITIONS - This document provides methods and materials related to | 08-23-2012 |
20120208719 | ASSESSING RHEUMATOID ARTHRITIS - This document provides methods and materials related to assessing mammals (e.g., humans) with arthritis (e.g., RA). For example, methods and materials for using cytokine response profiles to assist clinicians in assessing RA disease activity, assessing the likelihood of response and outcomes of RA therapy, predicting long-term RA disease outcomes, and assessing the risk of developing heart conditions are provided. Methods and materials for using cytokine response profiles to assist clinicians in diagnosing arthritis (e.g., RA) also are provided. | 08-16-2012 |
20120201446 | COMPUTER-AIDED DETECTION (CAD) OF INTRACRANIAL ANEURYSMS - A computer-aided system identifies aneurysm suspects in | 08-09-2012 |
20120197372 | PERCUTANEOUS PLACEMENT OF ELECTRODES - This document relates to methods and materials involved in delivering therapies to target tissue (e.g., a peripheral nerve). For example, methods and materials for placing and subsequently using leads to deliver electrical and/or drug therapies to target tissues (e.g., nerves and/or arteries) are provided. | 08-02-2012 |
20120196756 | DIGITAL SEQUENCE ANALYSIS OF DNA METHYLATION - The present invention relates to methods and compositions for determination of and uses of specific methylation patterns indicative of adenoma and carcinoma. In particular, the invention relates to analysis of defined CpG loci that are coordinately methylated in DNAs from cancer and adenoma samples, methods for identifying coordinately methylated loci, and methods of using analysis of coordinately methylated loci in one or more marker regions in the design of assays for adenoma and cancer. | 08-02-2012 |
20120190638 | METHODS OF TREATING HEMATOLOGIC CANCERS - This disclosure relates to the treatment of hematologic cancers, for example, cancers of the blood, by methods that include administration of EGCG and at least one of a purine nucleoside analog and an alkylating agent. In particular, methods of treating chronic lymphocytic leukemia (CLL) and acute lymphocytic leukemia (ALL) are described. | 07-26-2012 |
20120179063 | SYSTEMS, DEVICES AND METHODS FOR ASSESSMENT OF BODY CAVITY PRESSURES - Systems, devices and methods that can be used to obtain objective pressure measurements in a body cavity using one or more monitoring bladders mounted on a catheter. The monitoring bladders may be adapted to connect or be connected to a system capable of providing objective pressure measurements indicative of the compressive forces acting on the one or more monitoring bladder in the body cavity. The body cavity may include, for example, the rectum, esophagus, stomach, intestine, colon, reproductive tract, urethra, oronasopharnygeal tract, etc. | 07-12-2012 |
20120178114 | METHODS AND DEVICES FOR DETECTING THROMBIN GENERATION - Methods and devices for detecting thrombin generation are disclosed. Generally, the methods include combining a blood sample with a reagent composition so that reaction of the reagent composition and thrombin, if present in the sample, produces a detectable signal; and detecting the detectable signal. Generally, the devices include a fluid-tight material forming at least one passageway; a first chamber in fluid communication with at least one passageway; and at least one reagent disposed on a surface of or contained in either a chamber or a passageway. In some embodiments, the passageway is configured to permit capillary flow of fluid, while in other embodiments, fluid flow is accomplished through a pump functionally linked to at least one passageway. In some embodiments, the device may further include a signal detector positioned to detect a signal generated in a chamber or passageway. In certain embodiments, the device may further include a microprocessor functionally linked to the signal detector. | 07-12-2012 |
20120175398 | STAPLING APPARATUS AND METHODS OF ASSEMBLING OR OPERATING THE SAME - Stapling apparatus and methods of assembling or operating the stapling apparatus are described herein. The stapling apparatus described herein can be delivered through an overtube or other large channel. The stapling apparatus may, in various embodiments, allow for secure closure of, e.g., endoluminal openings such as, e.g., perforations, intentional viscerotomy (e.g., NOTES/full thickness resection), and other indications. | 07-12-2012 |
20120171207 | DEPLETING IMMUNOSUPPRESSIVE MONOCYTES WITHIN A MAMMAL - This document provides methods and materials involved in depleting immunosuppressive monocytes (e.g., CD14 | 07-05-2012 |
20120171192 | METHODS AND MATERIALS FOR MODULATING DEUBIQUITINASES AND UBIQUITINATED POLYPEPTIDES - This document relates to methods and materials involved in modulating deubiquitinases (e.g., USP10 polypeptides) and/or ubiquitinated polypeptides (e.g., tumor suppressor polypeptides or mutant versions of tumor suppressor polypeptides). For example, methods and materials for increasing deubiquitinase (e.g., a USP10 polypeptide) expression or activity, methods and materials for decreasing deubiquitinase (e.g., a USP10 polypeptide) expression or activity, methods and materials for stabilizing tumor suppressor polypeptides (e.g., wild-type p53 polypeptides), methods and materials for de-stabilizing mutant versions of tumor suppressor polypeptides (e.g., mutant p53 polypeptides), and methods and materials for reducing cancer cell proliferation, increasing cancer cell apoptosis, and/or treating cancer (e.g., cancers having reduced levels of wild-type p53 polypeptides or cancers having increased levels of mutant p53 polypeptides) are provided. This document also provides methods and materials for identifying agonists or antagonists of USP10 polypeptide mediated stabilization of p53 polypeptides. | 07-05-2012 |
20120165634 | DETECTING NEUROCHEMICAL OR ELECTRICAL SIGNALS WITHIN BRAIN TISSUE - This document relates to methods and materials involved in detecting neurochemical signals, electrophysiological signals, ions, or combinations thereof with brain tissue. For example, methods and materials for using probes to detect neurochemical signals (e.g., neurotransmitter concentrations), electrical signals, or combinations thereof during deep brain stimulation are provided. | 06-28-2012 |
20120150015 | SYSTEM AND METHOD FOR DETECTING HEALING ADJACENT TO IMPLANTED MEDICAL DEVICE - A method of detecting healing adjacent to an implanted medical device can first include pre-treating a surface of the medical device prior to implantation, thereby defining a pre-treated surface of the medical device. Then, subsequent to implantation, a portion of the pre-treated surface that is not covered by endothelial tissue is detected by a detection device. | 06-14-2012 |
20120143188 | ESOPHAGEAL MUCOSECTOMY SYSTEMS, DEVICES AND METHODS - Systems, devices, apparatus and methods that may be used for en bloc circumferential esophageal mucosal resection or ablation that can extend over only a selected portion or all of the length of the esophagus. | 06-07-2012 |
20120143099 | SYSTEMS AND METHODS FOR IMPAIRING SMOOTH MUSCLE TISSUE FUNCTION - Systems and methods for impairing smooth muscle tissue function using energy and/or pressure are described herein. The systems and/or methods may be used in some embodiments to target smooth muscle tissue in the bronchial passages. | 06-07-2012 |
20120141604 | NOVEL COMPOSITIONS AND METHODS FOR THE IDENTIFICATION, ASSESSMENT, PREVENTION AND THERAPY OF HUMAN CANCERS - The present invention is directed to the identification of markers that can be used to determine whether tumors are sensitive or resistant to a therapeutic agent. The present invention is also directed to the identification of therapeutic targets. The invention features a number of “sensitivity markers.” These are markers that are expressed in most or all cell lines that are sensitive to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are resistant to treatment with that agent. The invention also features a number of “resistance markers.” These are markers that are expressed in most or all cell lines that are resistant to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are sensitive to treatment with that agent. The invention also features marker sets that can predict patients that are likely to respond or not to respond to an agent. | 06-07-2012 |